Literature DB >> 18306274

Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function.

Thomas E Merchant1, Chia-Ho Hua, Hemant Shukla, Xiaofei Ying, Simeon Nill, Uwe Oelfke.   

Abstract

BACKGROUND: To determine whether proton radiotherapy has clinical advantages over photon radiotherapy, we modeled the dose characteristics of both to critical normal tissue volumes using data from patients with four types of childhood brain tumors. PROCEDURES: Three-dimensional imaging and treatment planning data, including targeted tumor and normal tissues contours, were acquired for 40 patients, 10 each with optic pathway glioma (OPG), craniopharyngioma (CR), infratentorial ependymoma (EP), or medulloblastoma (MB). Dose-volume data were collected for the entire brain, temporal lobes, cochlea, and hypothalamus from each patient. The data were averaged and compared based on treatment modality (protons vs. photons) using dose-cognitive effects models. Outcomes were estimated over 5 years.
RESULTS: Relatively small critical normal tissue volumes such as the cochlea and hypothalamus may be spared from radiation exposure when not adjacent to the primary tumor volume. Larger normal tissue volumes such as the supratentorial brain or temporal lobes receive less of the low and intermediate doses. When applied to longitudinal models of radiation dose-cognitive effects, these differences resulted in clinically significant higher IQ scores for patients with MB and CR and academic reading scores in patients with OPG. Extreme differences between proton and photon dose distributions precluded meaningful comparison of protons and photons for patients with EP.
CONCLUSIONS: Differences in the overall dose distributions, as indicated by modeling changes in cognitive function, showed that a reduction in the lower-dose volumes or mean dose would have long-term, clinical advantages for children with MB, CR, and OPG. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18306274     DOI: 10.1002/pbc.21530

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  93 in total

1.  Intensity modulated radiation therapy or stereotactic fractionated radiotherapy for infratentorial ependymoma in children: a multicentric study.

Authors:  Damien C Weber; Thomas Zilli; Hans Peter Do; Philippe Nouet; Fabienne Gumy Pause; Fabienne Gumy Pause; Alessia Pica
Journal:  J Neurooncol       Date:  2010-08-20       Impact factor: 4.130

2.  Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation.

Authors:  Daniel M Green; Thomas E Merchant; Catherine A Billups; Dennis C Stokes; Alberto Broniscer; Ute Bartels; Murali Chintagumpala; Timothy E Hassall; Sridharan Gururangan; Geoffrey B McCowage; John A Heath; Richard J Cohn; Michael J Fisher; Ashok Srinivasan; Giles W Robinson; Amar Gajjar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-05-19       Impact factor: 7.038

3.  Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma.

Authors:  Malin Blomstrand; N Patrik Brodin; Per Munck Af Rosenschöld; Ivan R Vogelius; Gaspar Sánchez Merino; Anne Kiil-Berthlesen; Klas Blomgren; Birgitta Lannering; Søren M Bentzen; Thomas Björk-Eriksson
Journal:  Neuro Oncol       Date:  2012-05-17       Impact factor: 12.300

4.  Technical Note: Optimization of spot and trimmer position during dynamically collimated proton therapy.

Authors:  Blake R Smith; Daniel E Hyer; Ryan T Flynn; Wesley S Culberson
Journal:  Med Phys       Date:  2019-03-05       Impact factor: 4.071

5.  Comparison of proton therapy and intensity modulated photon radiotherapy for locally advanced non-small cell lung cancer: considerations for optimal trial design.

Authors:  Taylor R Cushman; Vivek Verma; Jean-Claude M Rwigema
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

6.  Low- and middle-income countries can reduce risks of subsequent neoplasms by referring pediatric craniospinal cases to centralized proton treatment centers.

Authors:  Phillip J Taddei; Nabil Khater; Bassem Youssef; Rebecca M Howell; Wassim Jalbout; Rui Zhang; Fady B Geara; Annelise Giebeler; Anita Mahajan; Dragan Mirkovic; Wayne D Newhauser
Journal:  Biomed Phys Eng Express       Date:  2018-02-07

Review 7.  Assessment of the risk for developing a second malignancy from scattered and secondary radiation in radiation therapy.

Authors:  Harald Paganetti
Journal:  Health Phys       Date:  2012-11       Impact factor: 1.316

8.  Long-term health-related quality of life in pediatric brain tumor survivors receiving proton radiotherapy at <4 years of age.

Authors:  Bree R Eaton; Saveli Goldberg; Nancy J Tarbell; Miranda P Lawell; Sara L Gallotto; Elizabeth A Weyman; Karen A Kuhlthau; David H Ebb; Shannon M MacDonald; Torunn I Yock
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

9.  Analytical model for out-of-field dose in photon craniospinal irradiation.

Authors:  Phillip J Taddei; Wassim Jalbout; Rebecca M Howell; Nabil Khater; Fady Geara; Kenneth Homann; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2013-10-08       Impact factor: 3.609

Review 10.  Proton therapy for paediatric CNS tumours - improving treatment-related outcomes.

Authors:  Vinai Gondi; Torunn I Yock; Minesh P Mehta
Journal:  Nat Rev Neurol       Date:  2016-05-20       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.